MOMENTUS Perspective
-
Most Favored Nation (MFN) Is Altering Biopharma Drug Pricing Forever
Key Takeaways Target Audiences Innovative Biopharma Executives (US)Executives with assets in early stages of development or nearing US FDA approval, as well as those seeking ex-US launch partners. Big Pharma Executives in ex-US AffiliatesExecutives who are part of the OECD19 and simply trying to understand the pressures being faced by their global and US colleagues,
-
-
J.P. Morgan Healthcare Conference, the “Superbowl of Healthcare” – 2026 Watchlist
In December 2025, as we prepare for JP Morgan Healthcare on Jan 12-15, 2026, the U S Congress will be refining federal government funding of US Healthcare as influenced by the One Big Beautiful Bill Act (OBBBA). Spending on Medicare Part D drugs and overall Medicaid programs are once again in the cross hairs, and
-
-
Convergence of US FDA & Drug Pricing
The FDA, under new leadership, is taking an unprecedented role in drug pricing by linking approval incentives—like Priority Vouchers—to economic impact and Most Favored Nation (MFN) pricing. This blurs the traditional separation between regulatory review and payer negotiation, pressuring prices from day one. These shifts could reshape biopharma valuations, launch strategies, and access dynamics. Companies…
-
-
Industry Leaders Scott Roberts and John “Zeke” Czekanski Launch MOMENTUS Biopharma Consulting
LANTANA, Fla., Nov. 5, 2025 /PRNewswire/ — Industry leaders Scott Roberts and John “Zeke” Czekanski announced today they have partnered to form MOMENTUS Biopharma Consulting, LLC (“MOMENTUS” or “the Company”), a purpose-built strategic consulting group. Headquartered in Lantana, FL with an additional location in Boston, MA, MOMENTUS offers integrated strategic solutions across the therapeutic life cycle, sharpening the focus on value
-
